Abstract
Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
https://doi.org/10.1182/blood-2019-123961
Journal: Blood | Publication Date: Nov 13, 2019 |
Citations: 13 |
Exposure-Response Analyses Indicate a Promising Benefit/Risk Profile of Mosunetuzumab in Relapsed and Refractory Non-Hodgkin Lymphoma
Join us for a 30 min session where you can share your feedback and ask us any queries you have